丰原药业(000153) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥1,206,114,496.19, representing a 22.03% increase compared to ¥962,640,018.61 in the same period last year[3] - Net profit attributable to shareholders was ¥46,024,429.74, up 23.74% from ¥35,754,437.30 year-on-year[3] - The net profit excluding non-recurring gains and losses increased by 67.49% to ¥39,706,065.28 from ¥23,706,653.19 in the previous year[3] - Total operating revenue for Q1 2023 reached CNY 1,206,114,496.19, an increase of 21.9% compared to CNY 988,370,430.28 in Q1 2022[16] - Net profit attributable to the parent company was CNY 46,024,429.74, up 23.5% from CNY 37,194,242.35 in the same period last year[17] - Operating profit for the quarter was CNY 65,777,326.09, representing a 23.3% increase from CNY 53,357,909.46 in Q1 2022[16] - The total comprehensive income for the period was CNY 44,588,935.62, up from CNY 35,317,810.54 in the same quarter last year, an increase of 26.3%[17] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.1386, compared to CNY 0.1192 in Q1 2022, marking a 16.5% increase[17] Cash Flow - The company's cash flow from operating activities decreased by 29.16% to ¥20,045,680.47, down from ¥32,242,266.52 in the same period last year[3] - The net cash flow from operating activities for Q1 2023 was CNY 20,045,680.47, a decrease of 29.5% compared to CNY 28,298,762.02 in Q1 2022[19] - Total cash inflow from operating activities was CNY 1,034,532,225.52, while total cash outflow was CNY 1,014,486,545.05, resulting in a net cash inflow of CNY 20,045,680.47[19] - Cash flow from financing activities resulted in a net outflow of CNY 138,883,346.02, contrasting with a net inflow of CNY 5,805,131.14 in Q1 2022[19] - The ending balance of cash and cash equivalents was CNY 197,075,419.43, down from CNY 260,092,632.09 at the end of Q1 2022[19] - Total cash outflow for operating activities included CNY 84,892,708.85 in taxes paid, which increased significantly from CNY 39,729,421.07 in the previous year[19] - The company reported cash payments for purchasing goods and services amounting to CNY 679,553,466.73, an increase from CNY 653,899,669.92 in Q1 2022[19] Research and Development - R&D expenses surged by 102.31% to ¥25,035,890.83, compared to ¥12,375,233.91 in the previous year, indicating increased investment in innovation[7] - Research and development expenses increased significantly to CNY 25,035,890.83, up 102.7% from CNY 12,375,233.91 in the previous year[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,407,882,216.30, a decrease of 1.37% from ¥4,469,239,892.87 at the end of the previous year[3] - Total liabilities decreased to CNY 2,599,090,314.33 from CNY 2,714,477,751.55, a reduction of 4.2%[15] - The company's total equity increased to CNY 1,808,791,901.97, up from CNY 1,754,762,141.32, reflecting a growth of 3.1%[15] - The company's equity attributable to shareholders increased by 3.14% to ¥1,782,818,453.82 from ¥1,728,488,218.94 at the end of the previous year[3] Shareholder Information - The total number of common shareholders at the end of the reporting period is 50,171, with no preferred shareholders having restored voting rights[10] - The top 10 shareholders hold a total of 100% of the shares, with Anhui Wuwei Pharmaceutical Factory holding 10.79% (35,842,137 shares) and Anhui Bengbu Tushan Pharmaceutical Factory holding 7.68% (25,521,900 shares)[10] - The top 10 shareholders are involved in margin trading, with significant holdings through various securities accounts[11] Other Financial Metrics - The weighted average return on equity improved to 2.63%, up from 2.31% in the previous year[3] - The company recorded a 3769.82% increase in other operating expenses, amounting to ¥287,607.30, compared to ¥7,432.05 in the previous year, primarily due to increased asset write-off losses[9] - The company held a board meeting on April 7, 2023, to approve the revised plan for issuing shares to purchase assets and raise matching funds[12] - The company has implemented a restricted stock incentive plan in 2022, with certain shareholders holding restricted shares[11]